ClinicalTrials.gg
CompletedNCT04848779Updated Nov 13, 2026

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

An observational study in Glycogen Storage Disease Type II, sponsored by Sanofi. Completed at 15 sites in 9 countries. Open to participants aged 0 Days to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sanofi · Observational

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
9
Ages
0 Days to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Glycogen Storage Disease Type II by Sanofi — 4 open to participants now, 7 under way, 1 of them phase 3. Glycogen Storage Disease Type II · Sanofi.

Enrollment
8th of 10
9 · median 59
Started
2021
with 3 others
Observational
10 of 41
3 open now
Registered
36th of 41
by date

Among the 41 studies in Glycogen Storage Disease Type II by Sanofi, this one is the 8th largest by enrollment of the 10 observational ones that give a count, is one of 4 that started in 2021, is one of 10 observational ones, and was the 36th registered.

Glycogen Storage Disease Type II

162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.

Browse Glycogen Storage Disease Type II studies →

Open to participants now

4 of the 41 studies in Glycogen Storage Disease Type II by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.

This study: 0 Days to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Glycogen Storage Disease Type II by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To describe the effect of routine practice with alglucosidase alfa in patients with IOPD ≤6 months of age, on invasive ventilation-free survival after 52 weeks of treatment.

Secondary Objectives:

  • To describe the effect of routine practice with alglucosidase alfa on invasive ventilation-free survival and survival at 12 and 18 months of age, as well as on change in left ventricular mass (LVM) Z score, Alberta Infant Motor Scale (AIMS) score, body weight, body length, and head circumference Z scores, and urinary glucose tetrasaccharide (Hex4), at Week 52 of treatment.
  • To describe the safety, tolerability, and immunogenicity of alglucosidase alfa in the routine practice of IOPD treatment.
Read the detailed description

The planned duration of observation for each participant will be 104 weeks after enrollment, to determine secondary outcomes at 18 months (approximately 78 weeks) of age.

03

Conditions studied

  • Glycogen Storage Disease Type II
04

Who can participate

Ages eligible
0 Days to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Confirmly diagnosed IOPD patients 6 months or less of age (corrected for gestational age if needed), treated or planned to be treated with alglucosidase alfa, at the time of study inclusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of , participants must be ≤6 months of age, corrected for gestation if necessary. Gestational age \<40 weeks will be adjusted to a full-term gestational age of 40 weeks.
  • Participants must have alglucosidase alfa enzyme replacement therapy (ERT) planned or initiated for IOPD treatment irrespective of study participation, according to the treating physician's decision regarding participants' routine disease management.
  • Participants must have available and accessible medical records from the time of IOPD diagnosis and from subsequent follow-up.
  • Participants must have a confirmed diagnosis of IOPD, defined as presence of 2 pathogenic acid alpha glucosidase (GAA) variants and documented GAA deficiency in blood (dried blood spot [DBS] accepted), skin, or muscle tissue, or presence of 1 pathogenic GAA variant and documented GAA deficiency in blood, skin, or muscle tissue from separate samples (either from 2 different tissues or from the same tissue but at 2 different sampling dates.) (DBS and leukocytes are acceptable as 2 different samples from blood).
  • Participants must have established cross-reacting immunologic material (CRIM) status available prior to enrollment. CRIM status may be provided by historical CRIM testing results or prediction of CRIM status based on genotyping performed at a Clinical Laboratory Improvement Amendments (CLIA) or other appropriately certified genetic laboratory.
  • Participants must have cardiomyopathy at the time of diagnosis (LVMI equivalent to mean age-specific LVMI):

    • LVMI +1 standard deviation (SD) in participants diagnosed by newborn or sibling screening,
    • LVMI +2 SD in participants diagnosed by clinical evaluation.
  • Participants must have informed consent provided by parent(s)/legally acceptable representatives (LARs).

Exclusion criteria

Exclusion Criteria:

  • Participants with respiratory insufficiency, defined as:

    • Oxygen saturation \<90% on room air as determined by pulse oximetry,
    • Venous partial pressure of carbon dioxide (pCO2) >55 mmHg or arterial pCO2 >40 mmHg on room air,
    • Use of invasive (with intubation or tracheostomy) or noninvasive (no intubation or tracheostomy) ventilation at enrollment, for participants not having started ERT at enrollment,
    • Use of invasive or noninvasive ventilation at the time of ERT initiation, for participants having started ERT before enrollment.
  • Participants with major congenital abnormality including heart defect, neural tube defect, or Down syndrome that, in the opinion of the investigator, would preclude participation in the study or potentially decrease survival.
  • Participants with organic disease other than signs/symptoms related to Pompe disease, including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or circumstance that, in the opinion of the investigator, would preclude participation or potentially decrease survival.
  • Previous or ongoing treatment in any clinical trial of, or managed access program for, avalglucosidase alfa or any other Pompe disease-specific therapy.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
9 participants (actual)
Target follow-up
104 Weeks
Patient registry
Yes

Groups and cohorts

  • Cohort 1

    Drug: Alglucosidase alfa GZ419829

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants alive and free of invasive ventilation at Week 52 of treatment

    Time frame: Week 52

Secondary outcomes

  1. Proportion of participants alive and free of invasive ventilation at 12 and 18 months of age

    Time frame: at 12 and 18 months of age

  2. Proportion of participants alive at Week 52 of treatment

    Time frame: Week 52

  3. Proportion of participants alive at 12 months and 18 months of age

    Time frame: at 12 and 18 months of age

  4. Proportion of participants free of ventilator use and free of supplemental oxygen use at Week 52

    Time frame: Week 52

  5. Change from baseline to Week 52 in LVM Z score

    Time frame: from baseline to Week 52

  6. Change from baseline to Week 52 in AIMS score

    Time frame: from baseline to Week 52

  7. Change from baseline to Week 52 in body length Z-scores

    Time frame: from baseline to Week 52

  8. Change from baseline to Week 52 in body weight Z-scores

    Time frame: from baseline to Week 52

  9. Change from baseline to Week 52 in head circumference Z-scores

    Time frame: from baseline to Week 52

  10. Change from baseline to Week 52 in body length percentiles

    Time frame: from baseline to Week 52

  11. Change from baseline to Week 52 in body weight percentiles

    Time frame: from baseline to Week 52

  12. Change from baseline to Week 52 in head circumference percentiles

    Time frame: from baseline to Week 52

  13. Change from baseline to Week 52 in urinary Hex4

    Time frame: from baseline to Week 52

  14. Number of participants experiencing at least 1 treatment-emergent adverse events (TEAE), including infusion-associated reactions (IAR)

    Time frame: From inclusion for 104 weeks

  15. Number of participants with abnormalities in physical examinations

    Time frame: From inclusion for 104 weeks

  16. Number of participants with abnormalities in clinical laboratory results

    Time frame: From inclusion for 104 weeks

  17. Number of participants with abnormalities in vital signs measurements

    Time frame: From inclusion for 104 weeks

  18. Number of participants with abnormalities in 12-lead electrocardiogram (ECG)

    Time frame: From inclusion for 104 weeks

  19. Incidence of treatment-emergent antidrug antibodies (ADA)

    Time frame: From inclusion for 104 weeks

07

Study locations

15 sites
  • Advanced Medical Genetics- Site Number : 8400002
    Hawthorne, New York 10532, United States
  • Duke University Medical Center- Site Number : 8400004
    Durham, North Carolina 27710, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400001
    Cincinnati, Ohio 45229, United States
  • Le Bonheur Children's Hospital- Site Number : 8400005
    Memphis, Tennessee 38103, United States
  • Seattle Children's Hospital- Site Number : 8400003
    Seattle, Washington 98105, United States
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 2500001
    Tours, 37000, France
  • Investigational Site Number : 2760001
    Giessen, 35392, Germany
  • Investigational Site Number : 3800002
    Monza, Monza E Brianza 20052, Italy
  • Investigational Site Number : 3800001
    Florence, 50139, Italy
  • Investigational Site Number : 5280001
    Rotterdam, 3015 CE, Netherlands
  • Investigational Site Number : 7240001
    Esplugues de Llobregat, Catalunya [Cataluña] 08950, Spain
  • Investigational Site Number : 1580001
    Taipei, 100, Taiwan
  • Investigational Site Number : 8260001
    London, London, City of WC1N 3JH, United Kingdom
  • Investigational Site Number : 8260002
    Manchester, M13 9WL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2026, 64 months.

Of 29 observational studies under Glycogen Storage Disease Type II, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 33. This study's 64 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 19, 2021
StartActual
Jun 10, 2021
Primary completionActual
Oct 27, 2026
CompletionActual
Oct 27, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 13, 2026
Primary completion
Oct 28, 2026→Oct 27, 2026 (actual)
Nov 13, 2026
Study completion
Oct 28, 2026→Oct 27, 2026 (actual)
Nov 13, 2026
Enrollment
16 (estimated)→9 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Active, not recruiting→Completed
    Primary completion Oct 28, 2026→Oct 27, 2026 (now actual)
    Study completion Oct 28, 2026→Oct 27, 2026 (now actual)
    Enrollment 16 (estimated)→9 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04848779
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Jun 10, 2021
Primary completion
Oct 27, 2026
Completion
Oct 27, 2026
Last update
Nov 13, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion